

Special Issue

Frontiers in Flavivirus Vaccines

Message from the Guest Editors

The past three decades have been characterized by an unprecedented emergence of various zoonotic viral agents. Of these, viruses within the *Flavivirus* genus of the family *Flaviviridae* are of particular concern to human health, as demonstrated by the global spread of West Nile virus, the explosive outbreaks of Zika in the Americas, and the enormous disease burden of the four dengue viruses. While vaccines for some *Flaviviruses* (YFV, JEV, TBEV) do exist, there are regional disparities in availability and usage. With the trend towards urbanization, deforestation, and global travel facilitating greater human-animal contact as well as the spread of invasive arthropod vectors beyond their original ranges, additional and novel *Flavivirus* vaccines, vaccine formulations, and strategies will be critical going forward. To that end, the present Special Issue will address advances in, as well as novel *Flavivirus* vaccines, vaccination strategies, vaccine formulations or technologies, and animal models describing correlates of protection.

Guest Editors

Dr. Sasha R. Azar

Department of Pathology, University of Texas Medical Branch,
Galveston, TX 77555, USA

Dr. Carlos A. Sariol

Unit of Comparative Medicine, School of Medicine, University of Puerto Rico,
San Juan 00936, Puerto Rico

Deadline for manuscript submissions

closed (30 September 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/70483

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).